1-8 of 8
Serena J. Silver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract I003: Inhibitors of DHX9 RNA helicase as synthetic lethal cancer therapeutics

Free
Serena J Silver
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (11_Supplement): I003.
https://doi.org/10.1158/1538-8514.RNADRIVERS24-I003
Published: 14 November 2024
View articletitled, Abstract I003: Inhibitors of DHX9 RNA helicase as synthetic lethal cancer therapeutics
Journal Articles

Abstract PR006: Target validation and drug discovery efforts on exoribonuclease XRN1

Free
Maureen M. Lynes, Gordon J. Lockbaum, Brian A. Sparling, Sophie A. Shen, Sunaina P. Nayak, Kevin Knockenhauer, Simina Grigoriu, Shane M. Buker, Kenneth W. Duncan, Robert A. Copeland, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack-Sjodin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (11_Supplement): PR006.
https://doi.org/10.1158/1538-8514.RNADRIVERS24-PR006
Published: 14 November 2024
View articletitled, Abstract PR006: Target validation and drug discovery efforts on exoribonuclease XRN1
Journal Articles

Abstract PR001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability

Free
Maureen S. Lynes, Laura Ghisolfi, Sanjoy Khan, Taylor Hotz, Brian A. Sparling, Mary-Margaret Zablocki, Deepali Gotur, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Stephen J. Blakemore, Serena J. Silver, Robert A. Copeland
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): PR001.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-PR001
Published: 10 June 2024
View articletitled, Abstract PR001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability
Journal Articles

Abstract A001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability

Free
Maureen S. Lynes*, Laura Ghisolfi†, Sanjoy Khan, Taylor Hotz, Brian A. Sparling, Mary-Margaret Zablocki, Deepali Gotur, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Stephen J. Blakemore, Serena J. Silver, Robert A Copeland
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): A001.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-A001
Published: 10 June 2024
View articletitled, Abstract A001: KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability
Journal Articles

Abstract IA024: RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics

Free
Serena J Silver, Maureen M. Lynes, Brian A. Sparling, Jennifer Castro, Matthew H. Daniels, Sunaina Pai, Sophie A. Shen, David Brennan, Hyelee Lee, Gordon J. Lockbaum, Kevin Knockenhauer, Deepali Gotur, Simina Grigoriu, Shihua Yao, Shane Buker, Monique Laidlaw, Jie Wu, Stephen J. Blakemore, P. Ann Boriack-Sjodin, Kenneth W. Duncan, Jason A. Sager, Robert A. Copeland
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): IA024.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-IA024
Published: 10 June 2024
View articletitled, Abstract IA024: RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics
Journal Articles

Abstract A163: Exoribonuclease XRN1 is a therapeutic vulnerability in tumors with intrinsically elevated type I interferon signaling

Free
Maureen M Lynes, Sophie A Shen, Sunaina P Nayak, Brian A Sparling, Scott Ribich, Stephen J Blakemore, Serena J Silver
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A163.
https://doi.org/10.1158/1535-7163.TARG-23-A163
Published: 01 December 2023
View articletitled, Abstract A163: Exoribonuclease XRN1 is a therapeutic vulnerability in tumors with intrinsically elevated type I interferon signaling
Journal Articles

Abstract C087: DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer

Free
Jennifer Castro, Matthew H Daniels, David Brennan, Brian T Johnston, Rishabh Bansal, Monique Laidlaw, Chuang Lu, Deepali Gotur, Young-Tae Lee, Kevin Knockenhauer, April Case, Jie Wu, Anugraha Raman, Jae Eun Cheong, Julie Liu, Shane M Buker, E. Allen Sickmier, Stephen J Blakemore, P. Ann Boriack-Sjodin, Kenneth W Duncan, Serena J Silver, Scott Ribich, Robert A Copeland
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C087.
https://doi.org/10.1158/1535-7163.TARG-23-C087
Published: 01 December 2023
View articletitled, Abstract C087: DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer
Journal Articles

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Free
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J. Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J. Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J. Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2368–2380.
https://doi.org/10.1158/1535-7163.MCT-19-0170
Published: 02 December 2019
View articletitled, Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Open the PDF for Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers in another window
Includes: Supplementary data